Associated tags: Health, Heart, Science, Johnson & Johnson, Environment, JNJ, NYSE, Pharmaceutical industry, Pharmaceutical, Biotechnology
Locations: PENNSYLVANIA, CHINA, MA, MISSOURI, NEVADA, ASIA, HONG KONG, SANTANDER, JAPAN, TAIWAN, ROMANIA, ILLINOIS, NEW YORK CITY, PHILADELPHIA, LOS ANGELES, CHICAGO, APAC, UNITED STATES, NORTH AMERICA, NEW JERSEY, CANADA, ONTARIO, CZECH REPUBLIC, EUROPE, NEW YORK, WALL STREET, CALIFORNIA, GEORGIA, AF, PUERTO RICO, GA, TEXAS
Biotechnology,
Other Retail,
Health,
Retail,
Pharmaceutical,
Webcast,
Conference,
JNJ,
Eastern Time Zone,
Medtech,
Johnson & Johnson Johnson & Johnson (NYSE: JNJ) will participate in the 2024 RBC Capital Markets Global Healthcare Conference on Wednesday, May 15th, at the InterContinental Barclay Hotel, New York.
Key Points:
- Johnson & Johnson (NYSE: JNJ) will participate in the 2024 RBC Capital Markets Global Healthcare Conference on Wednesday, May 15th, at the InterContinental Barclay Hotel, New York.
- Tim Schmid, Executive Vice President, Worldwide Chairman, MedTech, will represent the Company in a session scheduled at 11:00 am (Eastern Time).
- The audio webcast replay will be available approximately 48-hrs after the webcast.
- View source version on businesswire.com: https://www.businesswire.com/news/home/20240408576293/en/
Cardiology,
Abstract,
Harvard Medical School,
Warfarin,
NACE,
Rivaroxaban,
Ventricular fibrillation,
Data analysis,
Risk,
Patient,
Stroke,
Research,
CSB,
American College,
Clinical trial,
PCI,
Bleeding,
Johnson & Johnson,
Percutaneous coronary intervention,
Pharmaceutical industry NEW BRUNSWICK, N.J., April 8, 2024 /PRNewswire/ -- Johnson & Johnson announced today a new analysis of data from the PIONEER AF-PCI clinical trial demonstrating that XARELTO® (rivaroxaban) was associated with a reduced risk of clinically significant bleeding (CSB), and net adverse clinical events (NACE; a composite of clinically significant bleeding [CSB] or major adverse cardiovascular event [MACE]) or rehospitalization compared to warfarin among both elderly and non-elderly patients with nonvalvular atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), a nonsurgical procedure designed to relieve narrowing or occlusion of the coronary artery.1,2 These data were featured in an oral presentation today at the American College of Cardiology 73rd Annual Scientific Session & Expo (ACC.24) in Atlanta, Georgia (Abstract #906-04).
Key Points:
- "Despite advances in cardiovascular care, patients with nonvalvular AF continue to be at risk of potentially life-threatening cardiovascular events, especially older patients considered difficult to treat due to multiple factors, including age and co-morbidities," said C. Michael Gibson*, M.D., CEO, of the nonprofit Baim Institute and professor of Medicine, Harvard Medical School.
- "A significant challenge in managing nonvalvular AF in older individuals undergoing PCI is determining a treatment that balances the prevention of stroke with the risk for bleeding.
- Results from the PIONEER AF-PCI trial reinforce the need to continue to research this complex and fragile elderly patient population."
- "With this new exploratory analysis at ACC.24, we're pleased to bring the latest research to healthcare providers that adds to the growing body of clinical evidence in older adults."
Guillain–Barré syndrome,
Bone marrow,
Medical College of Wisconsin,
Encephalopathy,
Survival,
Immunotherapy,
BCMA,
Patient,
Hypotension,
Mortality,
B-cell maturation antigen,
Edema,
Periodic breathing,
Associate professor,
Dexamethasone,
Certification,
Neutropenia,
Dizziness,
Risk,
Headache,
Chills,
Myelodysplastic syndrome,
Coagulopathy,
DPD,
Johnson & Johnson,
Immune system,
Effect,
Fatigue,
Thrombocytopenia,
Food,
Disease,
Drive,
Appetite,
Lymphocytopenia,
JNJ,
Constipation,
Multiple myeloma,
Acute myeloid leukemia,
CRS,
Death,
Hypersensitivity,
Cytopenia,
Cytokine release syndrome,
ASCO,
Use,
Hematology,
FDA,
PVD,
Annual general meeting,
T cell,
DSM-IV codes,
Incidence,
Tachycardia,
Bortezomib,
Diarrhea,
Viral,
Hope,
United,
Cough,
Daratumumab,
Nausea,
Society,
Division,
Physician,
Pharmaceutical industry HORSHAM, Pa., April 5, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.1 With this approval, CARVYKTI® becomes the first and only B-cell maturation antigen (BCMA)-targeted therapy approved for the treatment of patients with multiple myeloma as early as first relapse.
Key Points:
- "This milestone underscores our commitment to improve outcomes for patients and transform the treatment of multiple myeloma with CARVYKTI," said Jordan Schecter, M.D., Vice President, Disease Area Leader, Multiple Myeloma, Johnson & Johnson Innovative Medicine.
- CARVYKTI® is a cell therapy that works by harnessing a patient's immune system, or T cells, to fight the disease.
- Treatment requires extensive training, preparation, and certification to ensure a positive experience for patients.
- Since initial approval in February 2022, Johnson & Johnson has made significant advances in manufacturing to rapidly scale CARVYKTI® production.
Research,
Medical Devices,
Health Technology,
Cardiology,
Biotechnology,
Other Health,
Health,
Pharmaceutical,
Science,
Cardiovascular disease,
Worldwide,
Growth,
Peripheral artery disease,
Coronary artery disease,
Johnson & Johnson,
Patient,
PAD,
JNJ,
Perella Weinberg Partners,
Acquisition,
Electrophysiology,
Death,
IVL,
Medtech,
Ventricular fibrillation,
European,
PCI,
Artery,
Laminar,
Stenosis,
Hand,
Physician,
Percutaneous coronary intervention,
CAD,
Pharmaceutical industry Johnson & Johnson (NYSE: JNJ) and Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave”) today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 per share in cash, corresponding to an enterprise value of approximately $13.1 billion including cash acquired.
Key Points:
- Johnson & Johnson (NYSE: JNJ) and Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave”) today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 per share in cash, corresponding to an enterprise value of approximately $13.1 billion including cash acquired.
- The transaction is expected to accelerate revenue growth for both Johnson & Johnson and Johnson & Johnson MedTech.
- Delivers immediate operational accretion: The transaction will be accretive to operating margin for both Johnson & Johnson and Johnson & Johnson MedTech.
- Under the terms of the agreement, Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 per share in cash through a merger of Shockwave with a wholly owned Johnson & Johnson subsidiary.
Johnson & Johnson (NYSE: JNJ) today announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation of Ontario, Canada to purchase up to 1 million shares of Johnson & Johnson common stock at a price of $151.23 per share in cash.
Key Points:
- Johnson & Johnson (NYSE: JNJ) today announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation of Ontario, Canada to purchase up to 1 million shares of Johnson & Johnson common stock at a price of $151.23 per share in cash.
- The offer is for approximately 0.04% of the shares of Johnson & Johnson common stock outstanding as of the April 3, 2024 offer date.
- Johnson & Johnson is not associated in any way with TRC Capital Investment or its unsolicited mini-tender offer and recommends that shareholders do not tender their shares in response to TRC Capital Investment’s offer because the offer is at a price below the current market price for Johnson & Johnson’s shares and subject to numerous conditions.
- Johnson & Johnson recommends that shareholders who have not responded to TRC Capital Investment’s offer take no action.
Other Health,
Research,
General Health,
Pharmaceutical,
Oncology,
Medical Devices,
Health Technology,
Science,
Biotechnology,
Medical Supplies,
Other Science,
Health,
Community,
Organization,
White,
Health equity,
Male,
Empathy,
Health care,
Mortality,
City,
Spelman College,
Johnson & Johnson,
Hispanic and Latino Americans,
National Association,
Student,
Nursing,
J&J Johnson & Johnson announced today that it is collaborating with more than 100 community-led health organizations supporting historically marginalized communities across the United States — building on the Company’s multiyear, multimillion-dollar efforts to improve health equity.
Key Points:
- Johnson & Johnson announced today that it is collaborating with more than 100 community-led health organizations supporting historically marginalized communities across the United States — building on the Company’s multiyear, multimillion-dollar efforts to improve health equity.
- Supporting the work of grassroots organizations, community health centers and national associations is integral to identifying and implementing enduring healthcare solutions,” said Vanessa Broadhurst, Executive Vice President, Global Corporate Affairs at Johnson & Johnson.
- Black Women’s Health Imperative aims to empower Black women to take charge of their health through diabetes prevention and self-management classes.
- J&J recently held a Health Equity Innovation Challenge to support innovative solutions developed by entrepreneurs and start-ups.
Medical Supplies,
Medical Devices,
Health,
Health Technology,
Pharmaceutical,
Biotechnology,
Webcast,
Conference,
JNJ,
Eastern Time Zone,
Encore,
Johnson & Johnson Johnson & Johnson (NYSE: JNJ) will participate in the BofA Securities Health Care Conference on Tuesday, May 14th, at the Encore Hotel, Las Vegas, Nevada.
Key Points:
- Johnson & Johnson (NYSE: JNJ) will participate in the BofA Securities Health Care Conference on Tuesday, May 14th, at the Encore Hotel, Las Vegas, Nevada.
- John Reed, Executive Vice President, Innovative Medicine, R&D, will represent the Company in a session scheduled at 4:40 pm (Eastern Time).
- The audio webcast replay will be available approximately 48-hrs after the webcast.
- View source version on businesswire.com: https://www.businesswire.com/news/home/20240402572248/en/
Research,
Medical Supplies,
Other Health,
Biotechnology,
General Health,
Pharmaceutical,
Health,
Science,
Oncology,
Other Science,
Wolk,
Telephone,
Webcast,
JNJ,
Eastern Time Zone,
Johnson & Johnson,
Internet service provider Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 16th to review first-quarter results.
Key Points:
- Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 16th to review first-quarter results.
- Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call.
- The question and answer portion of the call will also include additional members of Johnson & Johnson’s executive team.
- A replay of the webcast will be available approximately three hours after the conference call concludes.
Cardiology,
Abstract,
Rivaroxaban,
Cardiovascular disease,
Worldwide,
Peripheral artery disease,
Health,
Atrial fibrillation,
Risk,
Patient,
Knowledge,
PAD,
Stroke,
Research,
Death,
Statistics,
American College,
Danger,
Johnson & Johnson,
Acute coronary syndrome,
Pharmaceutical industry NEW BRUNSWICK, N.J., April 4, 2024 /PRNewswire/ -- Johnson & Johnson announced today that clinical and real-world evidence from its cardiovascular portfolio will be featured at the American College of Cardiology 73rd Annual Scientific Session & Expo (ACC.24) taking place April 6-8, 2024, in Atlanta, Georgia. Eleven abstracts, including five oral presentations, will showcase data from Company-sponsored studies demonstrating therapeutic benefit of breakthrough medicines, such as XARELTO® (rivaroxaban), and interventional technologies, such as those from Abiomed® and Biosense Webster®, to help treat cardiovascular diseases, including atrial fibrillation (AF) and peripheral artery disease (PAD).
Key Points:
- "At ACC.24, we look forward to sharing the latest research and innovation from our broad portfolio, including XARELTO®, to equip clinicians and researchers with knowledge and insights that can help transform cardiovascular care for all."
- Johnson & Johnson is committed to elevating the standard of care in cardiovascular diseases and unlocking the potential of medicines and solutions of tomorrow.
- Several data presentations at ACC.24 demonstrate how the Company is improving outcomes for people living with cardiovascular disease, including older adults and other patient populations often considered hard to treat.
- The data we're presenting at ACC.24 demonstrate how we're continuing to deliver on our commitment," said Tim Schmid, Executive Vice President and Worldwide Chairman, Johnson & Johnson MedTech.
Diagnosis,
ESC,
Toxicity,
ERA,
Tadalafil,
Internal medicine,
European Respiratory Society,
Disease,
Risk,
Pulmonary hypertension,
Patient,
PVR,
Mitigation,
Female,
Nitric oxide,
Connective tissue disease,
Orthostatic hypertension,
World Health Organization,
PDE5,
Johnson & Johnson,
REMS,
WHO,
Pulmonary circulation,
PAH,
FDA,
Constriction,
ERS,
Food,
Pharmaceutical industry RARITAN, N.J., March 22, 2024 /PRNewswire/ -- Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved OPSYNVI® – a single-tablet combination of macitentan, an endothelin receptor antagonist (ERA), and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor – for the chronic treatment of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group I) and WHO functional class (FC) II-III.1 OPSYNVI® may be used in patients with PAH who are treatment-naïve or who are already on an ERA, PDE5 inhibitor or both. OPSYNVI® may be used in patients who are currently treated concomitantly with stable doses of macitentan 10 mg and tadalafil 40 mg (20 mg x 2) as separate tablets.1
Key Points:
- Historically, this required patients to take multiple pills because no single-tablet combination therapy targeting two or more pathways was available," said Kelly Chin, M.D., Professor of Internal Medicine and Director of the Pulmonary Hypertension Program at UT Southwestern Medical Center, and an investigator in the A DUE study.
- The FDA's approval of OPSYNVI® is based on the results from the pivotal Phase 3 A DUE study , in which OPSYNVI® demonstrated greater reduction in Pulmonary Vascular Resistance (PVR) after 16 weeks versus tadalafil or macitentan monotherapy.
- "People with PAH often live with the burden of taking many pills each day, which can pose challenges," said James F. List, M.D., Ph.D., Global Therapeutic Area Head, whose team oversees a portfolio of programs including Pulmonary Hypertension at Johnson & Johnson.
- "We're thrilled to bring this single-tablet combination therapy to patients, as it has the potential to optimize disease management and fulfill a significant unmet need in supporting recently updated treatment guidelines that call for initial or early combination treatment."
